natgillin/translations-raw huggingface dataset:
Metabolic acidosis Renal tubular acidosis
metabolna acidoza renalna tubulna cidoza
metabolic acidosis, alkalosis, decreased appetite
metabolična acidoza, alkaloza, zmanjšan tek
Metabolic acidosis1
metabolična acidoza1
Metabolic and endocrine effects
Vpliv na presnovo in žleze z notranjim izločanjem
Metabolic and transporter based interactions
Presnovne interakcije in interakcije na podlagi prenašalcev
Metabolic bone diseases (including hyperparathyroidism and Paget’s disease of the bone) other than primary osteoporosis or glucorticoid-induced osteoporosis.
Presnovne bolezni kosti (vključujoč hiperparatiroidizem in Pagetovo bolezen kosti) z izjemo primarne osteoporoze ali osteoporoze, povzročene z glukokorikoidi
metabolic disorders caused by the break-down products of dying cancer cells
presnovna bolezen zaradi razgradnih produktov umirajočih rakavih celic
Metabolic disorders: Loss of appetite
Presnovne motnje: izguba apetita.
Metabolic disturbances
Presnovne motnje
Metabolic enzyme inhibitors:Co-administration of nelfinavir with inhibitors of CYP2C19 (e.g., fluconazole, fluoxetine, paroxetine, lansoprazole, imipramine, amitriptyline and diazepam) may be expected to reduce the conversion of nelfinavir to its major active metabolite M8 (tert-butyl hydroxy nelfinavir) with a concomitant increase in plasma nelfinavir levels (see section 5.2).
Zaviralci presnovnih encimov: sočasno jemanje nelfinavirja z zaviralci CYP2C19 (npr. flukonazol, fluoksetin, paroksetin, lansoprazol, imipramin, amitriptilin in diazepam) lahko zmanjša pretvorbo nelfinavirja v njegov glavni aktivni presnovek M8 (terc-butil hidroksinelfinavir) in posledično poveča koncentracije nelfinavirja v plazmi (glejte poglavje 5.2).
Metabolic interactions
Presnovno medsebojno delovanje
Metabolic interactions are not considered likely, since ibandronic acid does not inhibit the major human hepatic P450 isoenzymes and has been shown not induce the hepatic cytochrome P450 system in rats (see section 5.2).
Presnovna medsebojna delovanja niso verjetna, ker ibandronska kislina pri ljudeh ne zavira glavnih jetrnih izoencimov P450, pri podganah pa ne spodbuja jetrnega citokroma P450 (glejte poglavje 5.2).
Metabolic interactions are not considered likely, since ibandronic acid does not inhibit the major human hepatic P450 isoenzymes and has been shown not to induce the hepatic cytochrome P450 system in rats (see section 5.2). .
Ibandronska kislina pri ljudeh ne zavira glavnih jetrnih izoencimov P450, pri podganah pa ne spodbuja jetrnega citokroma P450, zato presnovna medsebojna delovanja niso verjetna (glejte poglavje 5.2).
metabolised by CYP2C9 and co-administration
rosuvastatin se presnavljata s CYP2C9 in njuna
metabolised by CYP3A4 and lead to
se presnavljajo preko CYP3A4, in
metabolised by this enzyme.
ki jih ta encim presnavlja.
metabolised via the P450 3A
vključno s Cushingovim
Metabolisers:
presnavljajo preko CYP2C19:
Metabolism
16,1
Metabolism
Presnavljanje
Metabolism
Presnavljanje:
Metabolism
Presnovne in
Metabolism and
Presnovne in
Metabolism and
Presnovne in prehranske motnje
Metabolism and nutrition
Presnovne in prehranske
Metabolism and nutrition
Presnovne in prehranske motnje
Metabolism and nutrition disorders
balanitis in
Metabolism and nutrition disorders
Bolezni imunskega sistema
Metabolism and nutrition disorders
Bolezni jeter, žolčnika in žolčevodov
Metabolism and Nutrition Disorders
Bolezni krvi in
Metabolism and nutrition disorders
Bolezni živčevja
Metabolism and nutrition disorders
Neželeni učinki
Metabolism and nutrition disorders
Presnova pravastatina ne poteka s
Metabolism and nutrition disorders
Presnovne in
Metabolism and nutrition disorders
Presnovne in pehranske motnje
Metabolism and nutrition disorders
Presnovne in prehranske
Metabolism and nutrition disorders
Presnovne in prehranske motnje Občasni:
Metabolism and nutrition disorders
Presnovne in prehranske motnje Občasno:
Metabolism and nutrition disorders
Presnovne in prehranske motnje:
Metabolism and nutrition disorders
Srčne bolezni
Metabolism and nutrition disorders Common: anorexia, decreased appetite Not known: Dehydration
Presnovne in prehranske motnje pogosti: anoreksija, zmanjšan apetit neznana: dehidracija
Metabolism and nutrition disorders Common: decreased appetite (2.4% vs.
Presnovne in prehranske motnje
Metabolism and nutrition disorders Common: Mild hyperglycaemia* Not known: Insulin resistance*
Presnovne in prehranske motnje pogosti: blaga hiperglikemija* neznana: odpornost na insulin
Metabolism and nutrition disorders Very common: appetite lost
Presnovne in prehranske motnje Zelo pogosti: izguba apetita
Metabolism and nutrition disorders Very common: appetite lost
Presnovne in prehranske motnje Zelo pogosti: izguba apetita.
Metabolism and nutrition disorders:
Presnovne in prehranske motnje
metabolism and nutrition disorders: anorexia, decreased appetite, gastrointestinal disorders: stomach discomfort, dry mouth.
presnovne in prehranske motnje: anoreksija, zmanjšanje apetita bolezni prebavil: nelagodje v želodcu, suha usta.
metabolism and nutrition disorders: anorexia, decreased appetite, gastrointestinal disorders:stomach discomfort, dry mouth.
presnovne in prehranske motnje: anoreksija, zmanjšanje apetita bolezni prebavil: nelagodje v želodcu, suha usta.
Metabolism and nutritional disorders
Presnovne in prehranske motnje
Metabolism and nutritional disorders:
Presnovne in prehranske motnje:
Metabolism may play a more significant role in the elimination of sitagliptin in the setting of severe renal impairment or end-stage renal disease (ESRD).
Presnova ima lahko pomembnejšo vlogo pri izločanju sitagliptina pri hudi ledvični okvari ali pri končni ledvični odpovedi (ESRD – End-Stage Renal Disease).
Metabolism of doripenem to a microbiologically inactive ring-opened metabolite occurs primarily via dehydropeptidase-I.
Presnova doripenema do mikrobiološko neaktivnega presnovka z odprtim obročem poteka predvsem s pomočjo encima dehidropeptidaze-I.
Metabolism of imatinib is mainly hepatic, and only 13% of excretion is through the kidneys.
Presnova imatiniba poteka predvsem v jetrih in le 13 % se imatiniba izloča skozi ledvice.
Metabolism of imatinib is mainly hepatic, and only 13% of excretion is through the kidneys.
Presnova imatiniba poteka predvsem v jetrih in le 13 % se izloča skozi ledvice.
Metabolism studies in man have identified the corresponding acid, 1,1-(o,p'-dichlorodiphenyl) acetic acid (o,p’-DDA), as the major circulating metabolite, together with smaller quantities of the 1,1-(o,p'- dichlorodiphenyl)-2,2 dichloroethene (o,p’-DDE) analogue of mitotane.
Študije presnove pri človeku so pokazale, da je poglavitni presnovek v obtoku 1,1-(o,p'-diklorodifenil) ocetna kislina (o,p’-DDA) z manjšimi količinami analoga mitotana 1,1-(o,p'-diklorodifenil)-2,2 dikloroetena (o,p’-DDE).
metabolism)
oksidativne presnove)
metabolism, it is difficult to
težko napovedati njegovo
Metabolism/elimination
Presnova/izločanje
Metabolism:
Presnavljanje:
Metabolism:
Presnova:
Metabolism: bexarotene metabolites in plasma include 6- and 7-hydroxy-bexarotene and 6- and 7-oxo- bexarotene.
Metabolizem: Metaboliti beksarotena v plazmi vključujejo 6- in 7-hidroksi-beksaroten ter 6- in 7- okso-beksaroten.
Metabolism: Fluticasone furoate is rapidly cleared (total plasma clearance of 58.7 l/h) from systemic circulation principally by hepatic metabolism to an inactive 17-carboxylic metabolite (GW694301X), by the cytochrome P450 enzyme CYP3A4.
Presnova: Flutikazonfuroat se hitro očisti iz sistemske cirkulacije (skupni plazemski očistek 58,7 l/h), predvsem s presnovo v jetrih do neaktivnega 17-karboksilnega presnovka (GW694301X) z encimom CYP3A4 citokroma P450.
Metabolism: Low blood sugar levels
Presnova: nizka vrednost sladkorja v krvi
Metabolism: low blood sugar levels.
Presnova: nizka vrednost sladkorja v krvi.
Metabolism: Rasagiline undergoes almost complete biotransformation in the liver prior to excretion.
Presnova: Preden se izloči, se razagilin praktično popolnoma presnovi v jetrih.
Metabolite 14-OH clarithromycin Cmax  1.47 (1.21-1.80)
Cmax klaritromicinovega presnovka 14-OH  1,47 (1,21-1,80)
Metabolite 14-OH clarithromycin Cmin  0 (0.68-1.49)
Cmin klaritromicinovega presnovka 14- OH  0 (0,68-1,49)
Metabolite 25-O-desacetylrifabutin
AUC presnovka 25-O- dezacetilrifabutina
Metabolite 25-O-desacetylrifabutin
Cmin presnovka 25-O- dezacetilrifabutina
Metabolite H-1, N-methyl 3-hydroxymethyl dexmedetomidine O-glucuronide, is also a major circulating product of dexmedetomidine biotransformation.
Tudi presnovek H-1, N-metil 3-hidroksimetil deksmedetomidin O- glukuronid, je poglaviten produkt biotransformacije deksmedetomidina v krvi.
metabolite): AUC:↑30%
delamanida):
Metabolites include phenylcyclohexylglycolic acid, which is pharmacologically inactive, and N-desethyloxybutynin, which is pharmacologically active.
Med presnovki sta fenilcikloheksilglikolova kislina, ki je farmakološko neaktivna, in N-dezetiloksibutinin, ki je farmakološko aktiven.
Metabolites may be reduced or hydrolysed in the gastrointestinal tract by microbial flora, allowing reabsorption of the unconjugated active substance and metabolites (enterohepatic circulation).
Presnovke lahko mikrobna flora v prebavilih reducira ali hidrolizira, kar omogoči ponovno absorpcijo nekonjugirane zdravilne učinkovine in presnovkov (enterohepatični obtok).
Metabolites produced by aromatic and aliphatic hydroxylation or glucuronidation are present in very low levels and do not contribute to the overall antiviral activity of elvitegravir.
Presnovki, nastali z aromatsko in alifatsko hidroksilacijo ali presnovki glukuronidacije so prisotni v zelo nizkih ravneh in ne prispevajo k splošni protivirusni aktivnosti elvitegravirja.
metabolized by CYP3A4
dolgodelujočih opiatov, ki se
Metacam
Jakost
Metacam 0.5 mg/ml oral suspension for cats
Metacam 0,5 mg/ml, peroralna suspenzija za mačke
Metacam 0.5 mg/ml oral suspension for cats Meloxicam
Metacam 0,5 mg/ml, peroralna suspenzija za mačke Meloksikam
Metacam 0.5 mg/ml oral suspension for dogs
Metacam 0,5 mg/ml, peroralna suspenzija za pse
Metacam 0.5 mg/ml oral suspension for dogs Meloxicam
Metacam 0,5 mg/ml, peroralna suspenzija za pse Meloksikam
Metacam 1 mg chewable tablets for dogs Blisters: 7, 84 or 252 tablets.
Metacam 1 mg, žvečljive tablete za pse.
Metacam 1 mg chewable tablets for dogs Metacam 2.5 mg chewable tablets for dogs Meloxicam
Metacam 1 mg, žvečljive tablete za pse Metacam 2,5 mg, žvečljive tablete za pse Meloksikam
Metacam 1 mg chewable tablets for dogs Metacam 2.5 mg chewable tablets for dogs Meloxicam‌
Metacam 1 mg, žvečljive tablete za pse Metacam 2,5 mg, žvečljive tablete za pse Meloksikam‌
Metacam 1 mg chewable tablets for dogs Metacam 2.5 mg chewable tablets for dogs‌
Metacam 1 mg, žvečljive tablete za pse Metacam 2,5 mg, žvečljive tablete za pse‌
Metacam 1 mg chewable tablets for dogs: Blisters:
Metacam 1 mg, žvečljive tablete za pse: Pretisni omoti:
Metacam 1 mg chewable tablets for dogs: EU/2/97/004/043 7 tablets EU/2/97/004/044 84 tablets
Metacam 1 mg žvečljive tablete za pse: EU/2/97/004/043 7 tablet EU/2/97/004/044 84 tablet
Metacam 1 mg chewable tablets for dogs: Oral use.
Metacam 1 mg žvečljive tablete za pse: Peroralno
Metacam 1.5 mg/ml oral suspension for dogs
Metacam 1,5 mg/ml, peroralna suspenzija za pse
Metacam 1.5 mg/ml oral suspension for dogs Meloxicam
Metacam 1,5 mg/ml, peroralna suspenzija za pse Meloksikam
Metacam 1.5 mg/ml oral suspension for dogs or Metacam 1 mg and 2.5 mg chewable tablets for dogs may be used for continuation of treatment at a dosage of 0.1 mg meloxicam/kg body weight, 24 hours after administration of the injection.
Zdravljenje lahko nadaljujemo s peroralno suspenzijo Metacam 1,5 mg/ml za pse ali z žvečljivimi tabletami Metacam 1 mg in 2,5 mg za pse, ki jih damo v odmerku po 0,1 mg meloksikama na kilogram telesne mase 24 ur po injekciji.
Metacam 15 mg/ml oral suspension for horses
Metacam 15 mg/ml, peroralna suspenzija za konje
Metacam 15 mg/ml oral suspension for horses Meloxicam
Metacam 15 mg/ml, peroralna suspenzija za konje Meloksikam
Metacam 15 mg/ml oral suspension for pigs
Metacam 15 mg/ml, peroralna suspenzija za prašiče
Metacam 15 mg/ml oral suspension for pigs Meloxicam
Metacam 15 mg/ml, peroralna suspenzija za prašiče Meloksikam
Metacam 2 mg/ml solution for injection for cats
Metacam 2 mg/ml, raztopina za injiciranje za mačke
Metacam 2 mg/ml solution for injection for cats Meloxicam
Metacam 2 mg/ml, raztopina za injiciranje za mačke Meloksikam
Metacam 2,5 mg chewable tablets for dogs: EU/2/97/004/046 7 tablets
Metacam 2,5 mg žvečljive tablete za pse: EU/2/97/004/046 7 tablet
Metacam 2.5 mg chewable tablets for dogs Blisters: 7, 84 or 252 tablets.
Pretisni omoti: 7, 84 ali 252 tablet Metacam 2,5 mg, žvečljive tablete za pse Pretisni omoti: 7, 84 ali 252 tablet
Metacam 2.5 mg chewable tablets for dogs: Blisters:
Metacam 2,5 mg, žvečljive tablete za pse: Pretisni omoti:
Metacam 2.5 mg chewable tablets for dogs: Oral use.
Metacam 2,5 mg žvečljive tablete za pse: Peroralno
Metacam 20 mg/ml solution for injection for cattle, pigs and horses
Metacam 20 mg/ml, raztopina za injiciranje za goveda, prašiče in konje
Metacam 20 mg/ml solution for injection for cattle, pigs and horses Meloxicam
Metacam 20 mg/ml, raztopina za injiciranje za goveda, prašiče in konje Meloksikam
Metacam 40 mg/ml solution for injection for cattle and horses
Metacam 40 mg/ml, raztopina za injiciranje za govedo in konje
Metacam 40 mg/ml solution for injection for cattle and horses meloxicam
Metacam 40 mg/ml, raztopina za injiciranje za govedo in konje meloksikam
Metacam 5 mg/ml solution for injection for cattle and pigs
Metacam 5 mg/ml, raztopina za injiciranje za goveda in prašiče
Metacam 5 mg/ml solution for injection for cattle and pigs Meloxicam
Metacam 5 mg/ml, raztopina za injiciranje za goveda in prašiče Meloksikam
Metacam 5 mg/ml solution for injection for dogs and cats
Metacam 5 mg/ml, raztopina za injiciranje za pse in mačke
Metacam 5 mg/ml solution for injection for dogs and cats Meloxicam
Metacam 5 mg/ml, raztopina za injiciranje za pse in mačke Meloksikam
Metacam chewable tablets can be administered with or without food, are flavoured and are taken by most dogs voluntarily.
Žvečljive tablete Metacam lahko dajemo s hrano ali brez nje, imajo dodano aromo in jih večina psov vzame prostovoljno.
Metacam contains meloxicam, which belongs to a class of medicines called non-steroidal anti- inflammatory drugs (NSAIDs).
Zdravilo Metacam vsebuje meloksikam, ki spada v skupino zdravil, ki jim pravimo nesteroidna protivnetna zdravila (NSAID).
Metacam injection was studied in 60 calves with one group receiving Metacam and local anaesthetic and one group receiving a placebo (dummy) injection and local anaesthetic prior to dehorning.
Zdravilo Metacam v obliki injekcije je bilo proučeno pri 60 teletih, pri čemer je ena skupina prejela zdravilo Metacam in lokalni anestetik, druga pa placebo injekcijo (injekcijo brez zdravilne učinkovine) in lokalni anestetik pred odstranjevanjem rogov.
Metacam is a veterinary medicine that contains the active substance meloxicam.
Metacam je zdravilo za uporabo v veterinarski medicini, ki vsebuje zdravilno učinkovino meloksikam.
Metacam is available as an oral suspension, a solution for injection and chewable tablets.
Zdravilo Metacam je na voljo v obliki peroralne suspenzije, raztopine za injiciranje in žvečljivih tablet.
Metacam must not be administered in conjunction with other NSAIDs or glucocorticosteroids.
Metacama ne smemo dajati hkrati z drugimi nesteroidnimi protivnetnimi zdravili ali glukokortikosteroidi.
Metacam must not be administered in conjunction with other NSAIDs or glucocorticosteroids.
Metacama ne smemo dajati z drugimi nesteroidnimi protivnetnimi zdravili ali glukokortikosteroidi.
Metacam oral suspension was also comparable to ketoprofen for treatment of acute musculo-skeletal disorders in cats.
Metacam v obliki peroralne suspenzije je bilo za zdravljenje akutnih kostno-mišičnih obolenj pri mačkah primerljivo s ketoprofenom.
Metacam oral suspension was studied for treatment of musculoskeletal disorders associated with lameness in two studies and compared to treatment with vedaprofen.
Zdravilo Metacam v obliki peroralne suspenzije je bilo v dveh študijah proučeno za zdravljenje kostno- mišičnih obolenj, povezanih s šepavostjo, in primerjano z zdravljenjem z vedaprofenom.
Metacam showed improved lameness in horses at day 14 and at the final follow-up examination 2–4 days later than the vedaprofen treated group whilst the second study showed Metacam to be comparable to vedaprofen.
Z zdravilom Metacam je bila šepavost pri konjih občutno manjša 14. dan in pri končnem naknadnem pregledu dva do štiri dni kasneje, kot v skupini, ki je prejela vedaprofen.
Metacam significantly reduced lameness with 49% of the Metacam treated pigs with no lameness compared with 27% of the pigs which received the placebo treatment.
Pri prašičih je zdravilo Metacam občutno izboljšalo šepavost, ki je izginila pri 49 % prašičev, v primerjavi s 27 % v placebo skupini.
Metacam treated piglets had significantly reduced blood cortisol levels 30 minutes after castration compared with the control group.
Pujski, ki so prejeli zdravilo Metacam, so imeli 30 minut po kastraciji v krvi občutno nižje ravni kortizola v primerjavi s kontrolno skupino.
Metacam was comparable to flunixin in treating signs of infection and inflammation associated with puerperal septicaemia and toxaemia.
Zdravilo Metacam je bilo primerljivo s fluniksinom kar zadeva zdravljenje znakov okužbe in vnetja, povezanih s puerperalno septikemijo in toksemijo.
Metacam was comparable to vedaprofen in reducing pain associated with equine colic.
Zdravilo Metacam je bilo za lajšanje bolečine, povezane s koliko, primerljivo z vedaprofenom.
Metacam was effective from day 0–14 compared to the control group.
Zdravilo Metacam je učinkovalo 0–14 dni v primerjavi s kontrolno skupino.
metacresol , water for injections
metakrezol vodo za injekcije.
Metacresol Sodium chloride Trometamol Polysorbate 20
Metakrezol, natrijev klorid, trometamo,l polisorbat 20,
Metacresol Sodium chloride Trometamol Polysorbate 20
Metakrezol, natrijev klorid, trometamol, polisorbat 20,
Metaflumizone is an ectoparasiticide belonging to the semicarbazone group of compounds.
Metaflumizon je ektoparazitik, ki po sestavi spada v skupino semikarbazonov.
Metaflumizone is an insecticide belonging to the semicarbazone group of compounds.
Metaflumizon je insekticid, ki po sestavi spada v skupino semikarbazonov.
METAL CATION ANTACIDS
ANTACIDI S KOVINSKIMI KATIONI
metal cylinders with pressure control valves (body and and nozzle painted in white).
kovinski cilindri s tlačnim ventilom (belo pobarvano telo in odprtina).
metal cylinders with pressure control valves (body and nozzle painted in white).
kovinski cilindri s tlačnim ventilom (belo pobarvano telo in odprtina).
Metal impurities
Kovinske nečistote
METALLIC BOX / LEAD POT
KOVINSKA ŠKATLA/SVINČENI VSEBNIK
METALLIC CAN and OUTER CARTON
KOVINSKA POSODA in ZUNANJA ŠKATLA
Metallic taste
Bolezni prebavil
Metallic taste
kovinski okus
metallic taste
okus po kovini
metallic taste in the mouth dizziness
kovinski okus v ustih, omotičnost.
Metals to be included need to be based on the specific manufacturing process.
Pri kovinah, ki naj bi bile navedene, mora biti upoštevan specifičen proizvodni postopek.
Metalyse 10,000 units
Metalyse 10.000 enot
Metalyse 10,000 units powder and solvent for solution for injection
Metalyse 10.000 enot prašek in vehikel za raztopino za injiciranje tenekteplaza
Metalyse 8,000 units
Metalyse 8.000 enot
Metalyse 8,000 units powder and solvent for solution for injection
Metalyse 8.000 enot prašek in vehikel za raztopino za injiciranje tenekteplaza
Metalyse is incompatible with dextrose infusion solutions.
Zdravilo Metalyse je inkompatibilno z raztopino dekstroze.
Metalyse is incompatible with dextrose solution.
Zdravilo Metalyse je inkompatibilno z raztopino dekstroze.
Metalyse should be administered with caution in older people ( 75 years) due to a higher bleeding risk (see information on bleeding in section 4.4 and on the STREAM study in section 5.1).
Starejšim bolnikom (> 75 let) je treba zdravilo Metalyse zaradi večjega tveganja za pojav krvavitve dajati previdno (glejte podatke o krvavitvah v poglavju 4.4 in o študiji STREAM v poglavju 5.1).
Metalyse should be reconstituted by adding the complete volume of water for injections from the pre- filled syringe to the vial containing the powder for injection.
Zdravilo Metalyse moramo pripraviti tako, da dodamo ves volumen vode za injekcije iz napolnjene brizge v vialo s praškom za injiciranje.
Metalyse should not be used in people who have had an anaphylactic reaction (a severe, life- threatening allergic reaction) to tenecteplase, gentamicin (an ingredient found in the medicine) or any of the other ingredients.
Zdravilo Metalyse se ne sme uporabljati pri ljudeh, ki so imeli v preteklosti anafilaktično reakcijo (hudo, življenje ogrožajočo alergijsko reakcijo) na tenekteplazo, gentamicin (sestavino zdravila) ali katero koli drugo sestavino zdravila.
metastatic adenocarcinoma of the pancreas, as a first treatment in combination with another cancer medicine, gemcitabine. non-small cell lung cancer, as a first treatment in combination with the cancer medicine carboplatin when the patient cannot have surgery or radiotherapy.
metastatskega adenokarcinoma trebušne slinavke, pri katerem se uporablja kot zdravilo prve izbire v kombinaciji z drugim zdravilom za zdravljenje raka, tj. gemcitabinom; nedrobnoceličnega pljučnega raka, pri katerem se uporablja kot zdravilo prve izbire v kombinaciji z zdravilom proti raku, imenovanim karboplatin, pri bolnikih, pri katerih kirurški poseg ali obsevanje nista primerna.
Metastatic breast and ovarian cancer (second-line treatment)
Metastatski karcinom dojke in jajčnika (zdravljenje druggega izbora)
Metastatic Breast Cancer
Metastatski rak dojk
metastatic breast cancer, in combination with paclitaxel or capecitabine;
metastatskega raka dojke v kombinaciji s paklitakselom ali kapecitabinom;
Metastatic breast carcinoma, ovarian cancer and non-small cell lung carcinoma:
Metastatski karcinom dojke, rak jajčnika in nedrobnocelični karcinom pljuč:
metastatic cancer of the large intestine.
Metastatskega raka debelega črevesa.
metastatic cancer of the ovary (when the cancer has spread to other parts of the body).
z metastatskim rakom jajčnikov (rakom, ki se je razširil na druge dele telesa).
metastatic cancer of the ovary, when other treatments such as platinum-containing combination therapy have failed; non-small cell lung cancer, in combination with cisplatin, when patients cannot have surgery or radiation therapy.
metastatskega raka jajčnikov pri bolnicah, kjer drugi načini zdravljenja, na primer kombinirano zdravljenje z zdravili na osnovi platine, niso bili uspešni; nedrobnoceličnega pljučnega raka v kombinaciji z zdravilom cisplatin, če bolnik ne more biti operiran ali zdravljen z obsevanjem;
Metastatic carcinoma of the colon or rectum (mCRC)
Metastatski rak debelega črevesa in danke
metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies.
metastatskim kolorektalnim rakom, ki so bili predhodno že zdravljeni ali niso primerni za zdravljenja, ki so na voljo.
metastatic colorectal cancer (see section 5.1).
za zdravljenje metastatske oblike kolorektalnega raka (glejte poglavje 5.1).
metastatic colorectal cancer (see section 5.1).
zdravljenje metastatske oblike kolorektalnega raka (glejte poglavje 5.1);
Metastatic disease at baseline
metastatska bolezen pred začetkom zdravljenja
Metastatic disease, n (%)
Metastatska bolezen, n (%)
metastatic gastric cancer, with cisplatin and 5-fluorouracil head and neck cancer, with cisplatin and 5-fluorouracil.
za zdravljenje metastatskega raka želodca se uporablja v kombinaciji s cisplatinom in 5- fluorouracilom; za zdravljenje raka glave in vratu se zdravilo uporablja v kombinaciji s cisplatinom in 5- fluorouracilom.